RxDoctor Payments Data

Mitra Emami, MD

Neurology · San Jose, CANPI 1720145147

Payments from drug & device makers

$12,125in general payments, 2019–2025

Across 641 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$1K
  • Eisai Inc.$1K
  • AbbVie$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Catalyst Pharmaceuticals, Inc.$803
  • Biogen$689
  • plus $6K from 41 others

What the payments were for

  • Speaking & faculty fees$170%
  • Food & beverage$11,90298%
  • Education$2062%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$12,125 in reported general payments places this provider in the 70th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$198,954
Medicare patients
370
Services billed
4,225

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VumerityDiroximel Fumarate12$103,630
NamzaricMemantine Hcl/Donepezil Hcl26$29,736
NuedextaDextromethorphan Hbr/Quinidine12$18,320
RytaryCarbidopa/Levodopa19$15,435
QuliptaAtogepant13$14,030
Divalproex Sodium ErDivalproex Sodium52$3,382
Rivastigmine17$2,471
Memantine Hcl102$1,983
Carbidopa-LevodopaCarbidopa/Levodopa71$1,867
Mycophenolate Mofetil12$1,485
Levetiracetam30$1,333
Gabapentin68$1,330
Lacosamide23$967
Divalproex Sodium12$901
Oxcarbazepine18$722

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity$689$103,63012 claims
AbbVieNamzaric, Qulipta$1,073$43,76639 claims
Avanir Pharmaceuticals, Inc.Nuedexta$426$18,32012 claims
Amneal Pharmaceuticals LLCRytary, Mycophenolate Mofetil$137$16,92031 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,996 neurology providers in California.

Other neurology in San Jose

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →